OpenAI’s Sam Altman is becoming one of the most powerful people on Earth. We should be very afraid
By Gary Marcus,
The Guardian
| 08. 03. 2024
Image by TechCrunch from Flickr licensed under CC by 2.0
On 16 May 2023, Sam Altman, OpenAI’s charming, softly spoken, eternally optimistic billionaire CEO, and I stood in front of the US Senate judiciary subcommittee meeting on AI oversight. We were in Washington DC, and it was at the height of AI mania. Altman, then 38, was the poster boy for it all.
Raised in St Louis, Missouri, Altman was the Stanford dropout who had become the president of the massively successful Y Combinator startup incubator before he was 30. A few months before the hearing, his company’s product ChatGPT had taken the world by storm. All through the summer of 2023, Altman was treated like a Beatle, stopping by DC as part of a world tour, meeting prime ministers and presidents around the globe. US Senator Kyrsten Sinema gushed: “I’ve never met anyone as smart as Sam… He’s an introvert and shy and humble… But… very good at forming relationships with people on the Hill and… can help folks in government understand AI.” Glowing portraits at the...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
